An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

NCT02211222 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Lenvatinib

Sponsor

Eisai Inc.